CA2443128A1 - Distribution transdermique de pergolide - Google Patents

Distribution transdermique de pergolide Download PDF

Info

Publication number
CA2443128A1
CA2443128A1 CA002443128A CA2443128A CA2443128A1 CA 2443128 A1 CA2443128 A1 CA 2443128A1 CA 002443128 A CA002443128 A CA 002443128A CA 2443128 A CA2443128 A CA 2443128A CA 2443128 A1 CA2443128 A1 CA 2443128A1
Authority
CA
Canada
Prior art keywords
pergolide
delivery device
liquid
composition
matrix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002443128A
Other languages
English (en)
Inventor
Debra A. Martin
Jesus Miranda
Adolfo Leonel Vanegas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2443128A1 publication Critical patent/CA2443128A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne un dispositif de distribution transdermique comprenant une matrice multi-phase dotée d'un élément solide retenant les liquides auquel est associé du pergolide sous forme liquide, p. ex. un dispositif de distribution transdermique comprenant une couche barrière fixée sur une face de la matrice dotée en outre d'une face exposée. Une couche de montage est fixée sur la face exposée et une couche amovible est fixée sur l'autre face de la matrice. L'élément retenant les liquides peut par exemple être une matière absorbante, telle qu'une gaze de fibres naturelles ou synthétiques, un absorbant médical non tissé, une éponge naturelle et une éponge synthétique.
CA002443128A 2001-03-30 2002-04-01 Distribution transdermique de pergolide Abandoned CA2443128A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28053301P 2001-03-30 2001-03-30
US60/280,533 2001-03-30
PCT/US2002/010057 WO2002078602A2 (fr) 2001-03-30 2002-04-01 Distribution transdermique de pergolide

Publications (1)

Publication Number Publication Date
CA2443128A1 true CA2443128A1 (fr) 2002-10-10

Family

ID=23073490

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002443128A Abandoned CA2443128A1 (fr) 2001-03-30 2002-04-01 Distribution transdermique de pergolide

Country Status (4)

Country Link
EP (1) EP1385459A2 (fr)
JP (1) JP2005506297A (fr)
CA (1) CA2443128A1 (fr)
WO (1) WO2002078602A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10341317B4 (de) * 2003-09-03 2008-10-23 Axxonis Pharma Ag Transdermales therapeutisches System (TTS) zur Verabreichung von Ergolinverbindungen ausgenommen Pergolid
US20070243240A9 (en) * 2000-08-24 2007-10-18 Fred Windt-Hanke Transdermal therapeutic system
TW200514582A (en) * 2003-10-31 2005-05-01 Hisamitsu Pharmaceutical Co Transdermal preparation and method for reducing side effect in pergolide therapy
EP3936133A1 (fr) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Préparations et thérapies de substitution pour hormonothérapie naturelle combinée
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2947767A1 (fr) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Formulations d'hormones substitutives combinees naturelles et traitement hormonal substitutif
WO2015195448A1 (fr) * 2014-06-18 2015-12-23 Eli Lilly And Company Formulations transdermiques de pergolide et utilisations de celles-ci
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
US6572879B1 (en) * 1995-06-07 2003-06-03 Alza Corporation Formulations for transdermal delivery of pergolide

Also Published As

Publication number Publication date
WO2002078602A2 (fr) 2002-10-10
WO2002078602A3 (fr) 2003-02-20
EP1385459A2 (fr) 2004-02-04
JP2005506297A (ja) 2005-03-03

Similar Documents

Publication Publication Date Title
CA2443128A1 (fr) Distribution transdermique de pergolide
EP2123274B1 (fr) Composition médicinale pour une absorption transdermique, unité de stockage de la composition médicinale et préparation par absorption transdermique utilisant celle-ci
FI82602C (fi) Foerfarande foer framstaellning av verksamma plaoster.
JP5815556B2 (ja) 非結晶形態のロチゴチンの固体分散体を安定化するためのポリビニルピロリドン
JP2716231B2 (ja) 生理学的活性物質の投与のための吸蔵体
FI100857B (fi) Menetelmä välineen valmistamiseksi deksmedetomidiniinin transdermaalis ta antamista varten
US20170071870A1 (en) Transdermal Delivery of Cannabidiol with Other Active Moieties Including Cannabinoids
KR20160014064A (ko) 경피 전달 시스템
KR100995696B1 (ko) 펜타닐 경피 외용 접착제
KR101486599B1 (ko) 첩부제
WO2002078604A2 (fr) Administration transcutanee de materiau bioactif
US20080113013A1 (en) Transdermal, Therapeutic System With Activatable Oversaturation and Controlled Permeation Promotion
US11173131B2 (en) Transdermal device including porous microparticles
EP1865931B1 (fr) Timbre transdermique
KR101016914B1 (ko) 향상된 경피 송달 시스템
EP2650019B1 (fr) Timbre transdermique contenant un antidépresseur noradrénergique et sérotoninergique spécifique
US20040120995A1 (en) Transdermal delivery of pergolide
KR20020084161A (ko) 레리세트론 전달용 경피치료시스템
JP2011116757A (ja) リセドロネート経皮吸収製剤（２）
JP7399633B2 (ja) 経皮吸収型製剤の製造方法
Kharia et al. Overview of Transdermal Medicated Patches with its research updates in preceding years
SK281626B6 (sk) Transdermálny terapeutický systém s obsahom estradiolu
JP2011116756A (ja) ビスフォスフォネート経皮吸収製剤（２）
EP3810101A1 (fr) Système thérapeutique transdermique contenant de la rivastigmine
KR20180035859A (ko) 경피 전달 시스템

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead